Pharmaceutical composition for treating tumors and application thereof
By combining anthracycline drugs and immune checkpoint inhibitors, malignant tumors are treated, the problem of limited efficacy of the existing technology is solved, significant anti-tumor effects on a variety of malignant tumors are achieved, and the potential for clinical application is demonstrated. .
Patent Information
- Application Number
- CN202411155358.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art has limited efficacy in the treatment of malignant tumors, especially for some "cold tumors" such as pancreatic cancer, bone or soft tissue sarcoma, the single-drug treatment of immune checkpoint inhibitors is not effective, and targeted treatment has not yet been significant. Improve clinical benefits.
Combined use of anthracycline drugs and immune checkpoint inhibitors, and then administer anthracycline drugs such as doxorubicin, doxorubicin liposomes, daunorubicin and anti-PD-L1 antibodies and other immune checkpoints such as Inhibitors, treat tumors such as osteosarcoma, soft tissue sarcoma, head and neck squamous cell carcinoma, colorectal cancer, endometrial cancer, and breast cancer.
This combination drug regimen has shown significant synergistic effects in in vitro experiments and clinical practice, which is better than traditional standard drug regimens, has broad-spectrum anti-tumor effects on a variety of malignant tumors, and demonstrates effectiveness and safety, with a broad range of Clinical application prospects.
Smart Images

Figure CN118924904A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to the application of the combined use of anthracyclines and immune checkpoint inhibitors in treating malignant tumors or enhancing anti-tumor effects. Background Art
[0003] Surgical resection has always been the main treatment for BS, but due to frequent early recurrence and metastasis, especially metastasis to the lungs, the five-year survival rate of patients is less than 20%. However, with the introduction of perioperative chemotherapy and the use of key chemotherapy drugs, including doxorubicin (also known as adriamycin (ADM)), high-dose methotrexate (HD-MTX), cisplatin (DDP), high-dose ifosfamide (HD-I FO), and various combination therapies such as AP (ADM plus DDP), MAP (HD-MTX plus ADM and DDP) and IE (I FO plus etoposide), the treatment pattern of BS has undergone a complete paradigm shift. Taking OS as an example, by the end of the 1980s, the five-year survival rates of local and metastatic OS had exceeded 60% and 40%, respectively. Despite this, subsequent progress in treatment methods to further improve patient prognosis has been limited, and there are few clinically available medication options. Given the inherent heterogeneity and genomic complexity of BS, targeted therapy has not yet shown significant clinical benefits for it. Therefore, there is an urgent need to explore more effective treatment options for BS.
[0004] Along with surgery, radiotherapy, chemotherapy and targeted therapy, immunotherapy has been recognized as the fifth pillar of cancer treatment. Immunotherapy represented by immune checkpoint inhibitors (ICIs) has achieved considerable therapeutic effects in some cancers. However, some so-called "cold tumors" such as pancreatic cancer, bone or soft tissue sarcomas, etc., are generally not sensitive to ICI monotherapy. Therefore, how to better screen patients who may be sensitive to immunotherapy or its combination therapy, and to explore new and better drug treatment options to improve patients' clinical response rate and improve prognosis has become a clinical and scientific problem that needs to be solved urgently. Summary of the invention
[0005] The purpose of the present invention is to provide a pharmaceutical composition for treating tumors and its application.
[0006] Use of an anthracycline and an immune checkpoint inhibitor in the preparation of a medicament for treating a tumor or enhancing an anti-tumor effect in a subject, wherein the anthracycline and the immune checkpoint inhibitor are administered to the subject simultaneously or sequentially.
[0007] A pharmaceutical combination product of an anthracycline and an immune checkpoint inhibitor for use in treating a tumor or enhancing an anti-tumor effect in a subject, wherein the anthracycline and the immune checkpoint inhibitor are administered to the subject simultaneously or sequentially.
[0008] A method for treating tumors, comprising administering an effective amount of anthracycline and an immune checkpoint inhibitor simultaneously or sequentially to a subject in need thereof.
[0009] As in the aforementioned use, pharmaceutical combination product or method, the anthracycline drug is doxorubicin, liposome doxorubicin, epirubicin, daunorubicin, pirarubicin, legurubicin, or carrubicin.
[0010] As described above, the immune checkpoint inhibitor is an anti-PD-L1 antibody.
[0011] The use, pharmaceutical combination product or method as described above, wherein the tumor is osteosarcoma, soft tissue sarcoma, Ewing's sarcoma, head and neck squamous cell carcinoma, colorectal cancer, endometrial cancer, breast cancer, or gastric cancer.
[0012] A kit or a pharmaceutically acceptable composition comprising: an anthracycline drug and an immune checkpoint inhibitor.
[0013] As in the aforementioned kit or pharmaceutically acceptable composition, the anthracycline drug is doxorubicin, liposome doxorubicin, epirubicin, daunorubicin, pirarubicin, legurubicin, or carrubicin.
[0014] As in the aforementioned kit or pharmaceutically acceptable composition, the immune checkpoint inhibitor is an anti-PD-L1 antibody, and the anti-PD-L1 antibody is: atezolizumab, envolimab, adebelimumab, durvalumab, sugemalimab, socazolimab, etc.
[0015] The present invention provides a novel combined drug regimen for treating malignant tumors represented by BS: a combined drug regimen of anthracycline chemotherapy drugs and immune checkpoint inhibitors.
[0016] The researchers of the present invention have proved through experimental tests that the combined drug regimen provided by the present invention has the effect of effectively killing BS tumor cells, is superior to single-agent anthracycline chemotherapy drugs and single-agent immune checkpoint inhibitors, has significant synergistic effects, and is superior to the traditional standard drug regimen for BS.
[0017] The researchers of the present invention have proved through experimental tests that the combined drug regimen provided by the present invention shows an effective killing effect on the patient-derived organoid (PDO) model derived from osteosarcoma, soft tissue sarcoma, Ewing's sarcoma, head and neck squamous cell carcinoma, colorectal cancer, endometrial cancer, breast cancer, and gastric cancer patients, which can highly simulate the in vivo tumor immune microenvironment, and has a broad-spectrum anti-tumor effect.
[0018] The researchers of the present invention have proved through clinical practice that the drug combination provided by the present invention has demonstrated effectiveness and safety in the clinical treatment of patients with bone and soft tissue tumors. At present, the drug combination has not been included in the clinical guidelines related to the diagnosis and treatment of malignant tumors, and belongs to the off-label drug use (OLDU). Therefore, the drug combination has broad clinical application prospects, can provide support for subsequent larger-scale preclinical and clinical studies, and even eventually enter the clinical guidelines to benefit the majority of patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Figure 1: Optical microscopy images of three different independent organoids from primary PDOs from an osteosarcoma patient at indicated time points during culture.
[0020] Figure 2 Figure 2: Tumor tissue from an osteosarcoma patient and its corresponding primary PDO cultured in vitro for 14 days. The results of flow cytometry detection of the proportion of corresponding immune cell types in all living cells.
[0021] Figure 3 Primary PDO from 6 osteosarcoma patients were treated with doxorubicin alone, atezolizumab alone, doxorubicin and atezolizumab combination, and cisplatin, and then stained and fluorescent images were taken. The corresponding tumor growth inhibition (TGI) was calculated.
[0022] Figure 4 Primary PDO from 4 osteosarcoma patients were treated with doxorubicin liposome alone, atezolizumab alone, doxorubicin liposome and atezolizumab combination, and cisplatin, and then stained with fluorescent images. The corresponding tumor growth inhibition (TGI) was calculated.
[0023] Figure 5Primary PDO from three osteosarcoma patients were treated with doxorubicin alone, durvalumab alone, doxorubicin and durvalumab combination, and cisplatin, and then stained and fluorescent images were taken. The corresponding tumor growth inhibition (TGI) was calculated.
[0024] Figure 6 Primary PDO from three osteosarcoma patients were treated with doxorubicin liposome alone, durvalumab alone, doxorubicin liposome and durvalumab in combination, and cisplatin, followed by fluorescence staining and fluorescence images were taken, and the corresponding tumor growth inhibition (TGI) was calculated.
[0025] Figure 7 Primary PDO from three osteosarcoma patients were treated with doxorubicin alone, envoralizumab alone, doxorubicin and envoralizumab in combination, and cisplatin, and then stained and fluorescent images were taken. The corresponding tumor growth inhibition (TGI) was calculated.
[0026] Figure 8 Primary PDO from three osteosarcoma patients were treated with doxorubicin liposomes alone, envoralizumab alone, doxorubicin liposomes and envoralizumab in combination, and cisplatin, followed by fluorescence staining and fluorescence images. The corresponding tumor growth inhibition (TGI) was calculated.
[0027] Fig. 9 Figure 4: TGI results of multiple BS patients' PDO treated with different drug regimens.
[0028] Fig.10 Figure : TGI results after more different drug regimens were applied to the patients' PDO (n=75) in a retrospective cohort of 75 BS patients.
[0029] Fig.11 Figure 2: TGI results of the combination of doxorubicin and atezolizumab in PDO of different tumor types.
[0030] Fig.12: The upper left picture shows the medical record of a 47-year-old male patient (patient 01) with undifferentiated pleomorphic sarcoma (a type of soft tissue sarcoma) in the distal left femur; the lower left picture shows the Calcein-AM / PI live / dead cell double-stained fluorescence image of the patient's PDO after treatment with different drug regimens; the right picture shows the TGI results of each drug regimen after the patient's PDO was treated with different drug regimens.
[0031] Fig.13 : Enhanced magnetic resonance imaging (MRI) images of the legs of patient 01 collected at six different time points, including baseline, preoperative, and postoperative. The red arrows point to the primary tumor lesions.
[0032] Fig.14 : X-ray images of the legs of patient 01 collected at 6 different time points before and after surgery. The red arrow points to the primary tumor lesion.
[0033] Fig.15 : The upper left picture shows the medical record of a 20-year-old male patient (patient 02) with malignant peripheral nerve sheath tumor (a type of soft tissue sarcoma) in his right foot; the lower left picture shows the Calcein-AM / PI live / dead cell double-stained fluorescence image of the patient's PDO after treatment with different drug regimens; the right picture shows the TGI results of each drug regimen after the patient's PDO was treated with different drug regimens.
[0034] Fig.16 : Enhanced MRI images of the right foot of patient 02 collected at four different time points: baseline, preoperative, and postoperative. The red arrow points to the primary tumor lesion.
[0035] Fig.17 : Computed tomography (CT) chest plain scan images of patient 02 collected at six different time points, including baseline, preoperative, and postoperative. The red arrows point to the tiny metastatic lesions in the left lower lobe of the lung. DETAILED DESCRIPTION
[0036] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0037] The subject in the present invention refers to the subject of drug treatment or processing, including but not limited to:
[0038] Human patients: The most common subjects for drug treatment, including individuals of all ages, sexes, races, and with a variety of diseases or conditions.
[0039] Animals: including rats, dogs, cats, birds, fish, cows, sheep, pigs, monkeys, chickens and wild animals.
[0040] Patient-derived models: including organoids, primary cells, cell lines, patient-derived xenograft models (PDX), etc.
[0041] In the present invention, the anthracycline chemotherapy drug belongs to antitumor antibiotics, which are chemical substances with antitumor activity produced by microorganisms, and its basic structure is an anthracene ring connected to an amino sugar by a glycosidic bond. Anthracyclines have a broad spectrum of antitumor activity and are commonly used in standard treatment regimens for a variety of solid malignancies and hematological malignancies, and are often used in combination with other anticancer drugs. Anthracyclines severely interfere with DNA transcription and mRNA synthesis by intercalating between DNA base pairs; and can hinder topoisomerase II from reconnecting broken DNA double strands, destroying its tertiary structure, and inhibiting the DNA replication process; generating oxygen free radicals, destroying cell membrane function; having active effects throughout the cell cycle, and being most sensitive to G1 and S phase cells. The adverse reactions of anthracyclines are mainly manifested as cardiotoxicity, bone marrow suppression, gastrointestinal reactions, etc., and are dose-dependent. Anthracyclines include: Doxorubicin (also known as Adriamycin (ADM)), liposome doxorubicin, Epirubicin (also known as epirubicin, EPI), Daunorubicin (Daunorubicin, DNR), Pyrarubicin (also known as Pyrarubicin, THP), Legubicin (Legubicin), Carubicin (Carubicin), etc.
[0042] In the present invention, the immune checkpoint inhibitors (ICIs) can reactivate T cell-mediated anti-tumor immunity and reverse the immune escape phenomenon by blocking the immune checkpoint pathway, thereby promoting the death of tumor cells. Currently, ICI drugs approved for the treatment of malignant tumors mainly include programmed cell death receptor 1 (PD-1) inhibitors, programmed cell death ligand 1 (PD-L1) inhibitors, and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors. Anti-PD-L1 antibodies belong to PD-L1 inhibitors, which are monoclonal antibody immunotherapy drugs that can block the binding of PD-1 and PD-L1 by targeting PD-L1 on the surface of tumor cells, relieve the inhibitory state of the tumor immune microenvironment and T cell exhaustion, thereby enhancing the recognition of tumor cells by immune cells, activating their attack and killing activity, and achieving anti-tumor effects by mobilizing the body's own immune function. Currently on the market, the anti-PD-L1 antibody immune drugs include Atezolizumab (generic name: Atezolizumab, trade name: Tecentriq), Envafolimab (generic name: Envafolimab, trade name: Envida), Adebrelimab (generic name: Adebrelimab, trade name: Ariely), Durvalumab (generic name: Durvalumab, trade name: Imfinzi), Sugemalimab (generic name: Sugemalimab, trade name: Cejemly), Socazolimab (generic name: Socazolimab, trade name: Shankeyu), etc.
[0043] In the present invention, researchers of the present invention have constructed tumor organoids (PDO) from patients with osteosarcoma, soft tissue sarcoma, Ewing's sarcoma, head and neck squamous cell carcinoma, colorectal cancer, endometrial cancer, breast cancer, and gastric cancer that can simulate the tumor immune microenvironment in vivo with high simulation. Organoids are a "micro-organ" model derived from stem cells, cultured in vitro, and having a 3D structure. They can spontaneously self-renew, self-organize and differentiate to form a complex structure similar to a real tissue or organ, and can simulate the physiological and pathological characteristics and functions of the source tissue. The construction of PDO can be used for precision medicine for tumor patients, that is, using PDO to perform in vitro sensitivity tests of different drug regimens in parallel, and assisting or even guiding the formulation of clinical treatment plans for corresponding patients based on the test results. In addition, due to the convenience of PDO as an in vitro model, preclinical efficacy evaluation of new drugs and "new uses of old drugs" (i.e., new combinations of marketed drugs and new indications for expansion research) can also be carried out, thereby providing a leading solid basis for subsequent preclinical research, clinical research, and even clinical wide application. The researchers of the present invention found through in vitro drug sensitivity detection of PDO that the combination of anthracycline chemotherapy drugs and immune checkpoint inhibitors has the effect of effectively killing tumor cells of various cancers. Moreover, in PDO of bone sarcoma (BS), the combination of anthracycline chemotherapy drugs and immune checkpoint inhibitors is better than anthracycline chemotherapy drugs alone and immune checkpoint inhibitors alone, has a significant synergistic effect, and is better than the traditional standard medication regimen of BS. Further, the researchers of the present invention have proved through clinical practice that the combination of anthracycline chemotherapy drugs and immune checkpoint inhibitors has demonstrated effectiveness and safety in the clinical treatment of patients with bone and soft tissue tumors.
[0044] Therefore, the combination of anthracycline chemotherapy drugs and immune checkpoint inhibitors can be used as a potential new treatment for malignant tumors represented by BS. Since this combination has not yet been included in the clinical guidelines for the diagnosis and treatment of malignant tumors, it is an off-label use. Therefore, this combination has broad prospects for clinical application and can provide support for subsequent larger-scale preclinical and clinical studies, and may even eventually enter clinical guidelines to benefit a large number of patients.
[0045] The following is a description of the construction, validation, and drug sensitivity testing experiments of patient-derived tumor organoids, as well as methods for guiding patient clinical treatment based on drug sensitivity test results.
[0046] ①Organoid construction experiment:
[0047] Fresh tumor specimens from patients obtained from core needle biopsy (approximately 2-3 puncture strips) or open surgery (approximately the size of a broad bean) are placed in tubes containing pre-cooled preservation solution and transported to the laboratory within 48 hours at approximately 4°C.
[0048] In a clean bench, immerse the sample in washing buffer, trim to remove necrotic, calcified or fatty tissue, and wash three times in a 15 mL centrifuge tube for 1 min each time.
[0049] Cut the tissue into small pieces (1 mm 3 ~2mm 3 ), enzymatic hydrolysis was performed at 37°C for 15-60 min until at least 70% of the tissue was dissociated into cell clusters of 40-50 μm in size, and then the enzymatic hydrolysis was terminated with neutralization buffer.
[0050] The cell pellet was washed and resuspended, and then mixed with matrix gel at a concentration of 1-5×10 4 The cells were seeded into 96-well plates at a density of 10 cells / ml, and then the corresponding cancer-specific organoid culture medium was added. Thereafter, the growth status of the organoids was closely monitored under an optical microscope every day.
[0051] ② Use flow cytometry to compare the main immune cell types in the organoids with the tumor tissue from which they are derived to verify that the organoids retain the immune microenvironment in the tissue:
[0052] Organoids and their derived tumor tissues were digested into single-cell suspensions, and multicolor flow cytometry was used to analyze the number and proportion of immune cell subsets in each sample.
[0053] The staining antibodies included CD45 antibody (for marking all leukocytes; Biolegend, 1:100), CD3 antibody (for marking CD3+ T cells; Biolegend, 1:100), CD4 antibody (for marking CD4+ T cells; Biolegend, 1:100), CD8 antibody (for marking CD8+ T cells; Biolegend, 1:100), CD56 antibody (for marking CD56+ NK cells; Biolegend, 1:100), CD14 antibody (for marking CD14+ monocytes / macrophages; Biolegend, 1:100), and CD11c antibody (for marking CD11c+ dendritic cells; Biolegend, 1:100).
[0054] Data obtained by flow cytometry were analyzed using FlowJo v10.8.1.
[0055] ③Organoid drug sensitivity detection experiment:
[0056] After inoculation, the growth status of the organoids is closely monitored under an optical microscope every day. Once the organoids reach a state of morphological visibility under an optical microscope (usually 4 to 7 days after inoculation), they are treated with drugs for 4 days, and the drug concentration applied is the maximum blood drug concentration (Cmax) observed in the corresponding clinical study of the drug.
[0057] The selection of drug regimens for organoid drug sensitivity testing includes anthracycline chemotherapy alone, immune checkpoint inhibitors alone, and combination therapy of anthracycline chemotherapy and immune checkpoint inhibitors; as well as drug regimens based on the patient's clinical testing needs, mainly based on authoritative clinical practice guidelines (such as guidelines issued by the National Comprehensive Cancer Network (NCCN) and the Chinese Society of Clinical Oncology (CSCO), covering standard medication regimens), clinical studies and trials included in PubMed, recommendations of the Multidisciplinary Treatment Collaborative Team (MDT), and other evidence-based medicine bases.
[0058] On the fourth day of drug-treated organoids, the culture medium was removed, the organoids were washed with phosphate buffered saline (PBS), and then the PBS was removed. An appropriate volume of Calcein-AM / Propidium iodide (PI) detection working solution was added, and the organoids were incubated at 37°C in the dark for 30 minutes to perform fluorescent staining of the organoids using the Calcein-AM / PI live cell / dead cell double staining method. After the incubation, the working solution was removed and washed with PBS. Fresh culture medium was added, and the organoids were photographed and detected under a fluorescence microscope (Calcein-AM emits green fluorescence, Ex / Em=490 / 515nm; PI emits red fluorescence, Ex / Em=535 / 617nm). Calcein-AM can fluorescently stain live cells, while PI can stain dead cells.
[0059] Green fluorescent stained organoids with clear edges and a diameter ≥30 μm were counted as live organoids, and the ratio of live organoids in the drug-treated group to the live organoids in the control group (without any drug treatment) was calculated to obtain the tumor growth inhibition rate (TGI) value of each drug regimen on the organoids.
[0060] ④ Clinical treatment of patients guided by organoid drug sensitivity test results:
[0061] Whether patients adopt the sensitive results obtained by organoid drug sensitivity testing for clinical treatment is mainly based on clinical decision-making. For patients who have not benefited from the previous standard treatment or are considered by the MDT to be unresponsive to the previous treatment, after comprehensive consideration by the attending physician and full knowledge of the patient, the recommended medication regimen with a higher TGI in the organoid drug sensitivity test results can be used for subsequent clinical treatment.
[0062] We screened out 2 cases of patients with bone and soft tissue tumors who received the recommended medication regimen of anthracycline chemotherapy drugs combined with immune checkpoint inhibitors, underwent clinical treatment with this combination therapy after comprehensive clinical decision-making, and had subsequent follow-up results. The corresponding clinical follow-up results demonstrated the effectiveness and safety of this combination therapy.
[0063] from Figure 1 It can be seen that this is the morphology of an in vitro cultured, primary, osteosarcoma patient's PDO under an optical microscope, showing an irregular spherical shape characterized by dense edges and transparent cavities. In the figure, "a", "b", and "c" mark three different independent organoids in the same sample, and the black short line is the scale (100μm). The different time points (nth day) during the culture process are marked above the figure. This figure, as a representative of the embodiment, confirms the successful culture of PDO by the researchers of the present invention.
[0064] from Figure 2 It can be seen that this is a tumor tissue of an osteosarcoma patient and its corresponding primary PDO that has been cultured in vitro for 14 days. The main immune cell types that should be present in the tumor microenvironment are detected by flow cytometry, and the proportion of the corresponding immune cell types in all living cells is calculated as the result presented. After 14 days of in vitro culture, the main immune cell types in the primary PDO were retained or even amplified compared with their corresponding source tissues. Moreover, this 14-day time window meets the needs of PDO growth, drug treatment, and drug sensitivity result detection. This figure, as a representative of the embodiment, confirms that the PDO cultured by the researchers of the present invention can maintain the immune microenvironment in the source tissue during the drug sensitivity test, and can retain the key cell types required for ICI drugs to exert their efficacy, and therefore can be used to detect the sensitivity of tumor cells to ICI drugs.
[0065] from Figure 3It can be seen that this is the result of a drug sensitivity test experiment on primary PDO (OS-PDO-1, -2, -3, -4, -5, -7) of 6 patients with osteosarcoma. The picture was taken under a fluorescence microscope with a magnification of 10×. In the experiment, 6 organoids were treated with doxorubicin (anthracycline chemotherapy drug) alone, atezolizumab (anti-PD-L1 antibody immune drug) alone, doxorubicin and atezolizumab combined, and cisplatin (traditional standard medication for osteosarcoma), respectively, and PDO without any drug was used as a control. After the treatment, the Calcein-AM / PI live cell / dead cell double staining method was used for staining, photography, and counting of live organoids, and then the ratio of live organoids in the drug-treated group to live organoids in the control group was calculated, and the TGI of each medication regimen on the corresponding organoid was obtained and marked on the picture. It can be seen that in PDOs from different osteosarcoma patients, the combination of doxorubicin and atezolizumab has the effect of effectively killing tumor cells, which is more effective than either single drug, and the two have a significant synergistic effect. In addition, the combination of doxorubicin and atezolizumab is more effective than cisplatin, and shows an effect superior to the traditional standard medication regimen for osteosarcoma treatment in killing tumor cells.
[0066] from Figure 4 It can be seen that this is the result of a drug sensitivity test experiment on primary PDO (OS-PDO-1, -2, -3, -4) of 4 patients with osteosarcoma. The picture was taken under a fluorescence microscope with a magnification of 10×. In the experiment, 4 organoids were treated with doxorubicin liposomes (liposomal formulation of anthracycline chemotherapy drug doxorubicin) alone, atezolizumab (anti-PD-L1 antibody immune drug) alone, doxorubicin liposomes and atezolizumab combined with cisplatin (traditional standard medication for osteosarcoma), and PDO without any drug was used as a control. After the treatment, the Calcein-AM / PI live / dead cell double staining method was used for staining, photography, and counting of live organoids, and then the ratio of live organoids in the drug-treated group to live organoids in the control group was calculated to obtain the TGI of each medication regimen on the corresponding organoids and mark them on the picture. It can be seen that in PDOs from different osteosarcoma patients, the combination of doxorubicin liposomes and atezolizumab has the effect of effectively killing tumor cells, which is more effective than either single drug, and the two have a significant synergistic effect. In addition, the combination of doxorubicin liposomes and atezolizumab is more effective than cisplatin, and shows an effect superior to the traditional standard medication regimen for osteosarcoma treatment in killing tumor cells.
[0067] from Figure 5It can be seen that this is the result of a drug sensitivity test experiment on primary PDO (OS-PDO-1, -2, -3) of three patients with osteosarcoma. The picture was taken under a fluorescence microscope with a magnification of 10×. In the experiment, three organoids were treated with doxorubicin (anthracycline chemotherapy drug) alone, durvalumab (anti-PD-L1 antibody immune drug) alone, a combination of doxorubicin and durvalumab, and cisplatin (the traditional standard medication for osteosarcoma), respectively, with PDO without any drug as the control. After the treatment, the Calcein-AM / PI live / dead cell double staining method was used for staining, photography, and counting of live organoids, and then the ratio of live organoids in the drug-treated group to live organoids in the control group was calculated to obtain the TGI of each medication regimen on the corresponding organoids and mark them on the picture. It can be seen that in PDOs from different osteosarcoma patients, the combination of doxorubicin and durvalumab has the effect of effectively killing tumor cells, which is more effective than either single drug, and the two have a significant synergistic effect. In addition, the combination of doxorubicin and durvalumab is more effective than cisplatin, and shows an effect superior to the traditional standard medication regimen for osteosarcoma treatment in killing tumor cells.
[0068] from Figure 6 It can be seen that this is the result of a drug sensitivity test experiment on primary PDO (OS-PDO-1, -2, -3) of three patients with osteosarcoma. The picture was taken under a fluorescence microscope with a magnification of 10×. In the experiment, three organoids were treated with doxorubicin liposomes (liposomal formulation of anthracycline chemotherapy drug doxorubicin) alone, durvalumab (anti-PD-L1 antibody immune drug) alone, doxorubicin liposomes and durvalumab combined, and cisplatin (traditional standard medication for osteosarcoma), respectively, with PDO without any drug as the control. After the treatment, the Calcein-AM / PI live / dead cell double staining method was used for staining, photography, and counting of live organoids, and then the ratio of live organoids in the drug-treated group to live organoids in the control group was calculated to obtain the TGI of each medication regimen on the corresponding organoids and mark them on the picture. It can be seen that in PDOs from different osteosarcoma patients, the combination of doxorubicin liposomes and durvalumab has the effect of effectively killing tumor cells, which is more effective than either single drug, and the two have a significant synergistic effect. In addition, the combination of doxorubicin liposomes and durvalumab is more effective than cisplatin, and shows an effect superior to the traditional standard medication regimen for osteosarcoma treatment in killing tumor cells.
[0069] from Figure 7It can be seen that this is the result of a drug sensitivity test experiment on primary PDO (OS-PDO-1, -4, -5) of three patients with osteosarcoma. The picture was taken under a fluorescence microscope with a magnification of 10×. In the experiment, three organoids were treated with doxorubicin (anthracycline chemotherapy drug) alone, Envoli monoclonal antibody (anti-PD-L1 antibody immune drug) alone, a combination of doxorubicin and Envoli monoclonal antibody, and cisplatin (the traditional standard medication for osteosarcoma), respectively, with PDO without any drug as the control. After the treatment, the Calcein-AM / PI live cell / dead cell double staining method was used for staining, photography, and counting of live organoids, and then the ratio of live organoids in the drug-treated group to live organoids in the control group was calculated to obtain the TGI of each medication regimen on the corresponding organoids and mark them on the picture. It can be seen that in PDOs from different osteosarcoma patients, the combination of doxorubicin and Envolizumab has the effect of effectively killing tumor cells, which is more effective than either single drug, and the two have a significant synergistic effect. In addition, the combination of doxorubicin and Envolizumab is more effective than cisplatin, and shows an effect superior to the traditional standard medication regimen for osteosarcoma treatment in killing tumor cells.
[0070] from Figure 8 It can be seen that this is the result of a drug sensitivity test experiment on primary PDO (OS-PDO-1, -4, -6) of 3 patients with osteosarcoma. The picture was taken under a fluorescence microscope with a magnification of 10×. In the experiment, 3 organoids were treated with doxorubicin liposomes (liposomal formulation of anthracycline chemotherapy drug doxorubicin) alone, Envoli monoclonal antibody (anti-PD-L1 antibody immune drug) alone, a combination of doxorubicin liposomes and Envoli monoclonal antibody, and cisplatin (the traditional standard medication regimen for the treatment of osteosarcoma), respectively, and PDO without any drug was used as a control. After the treatment, the Calcein-AM / PI live cell / dead cell double staining method was used for staining, photography, and counting of live organoids, and then the ratio of live organoids in the drug-treated group to live organoids in the control group was calculated, and the TGI of each medication regimen on the corresponding organoids was obtained and marked on the picture. It can be seen that in PDOs from different osteosarcoma patients, the combination of doxorubicin liposomes and Envolizumab has the effect of effectively killing tumor cells, which is more effective than either single drug, and the two have a significant synergistic effect. In addition, the combination of doxorubicin liposomes and Envolizumab is more effective than cisplatin, and shows an effect superior to the traditional standard medication regimen for osteosarcoma treatment in killing tumor cells.
[0071] from Fig. 9It can be seen that this is the TGI result after the PDO of multiple BS patients were treated with different drug regimens. These drug regimens include: doxorubicin alone, atezolizumab alone, pembrolizumab (anti-PD-1 antibody immune drug) alone, the combination of doxorubicin and atezolizumab, and several other combination regimens containing the above-mentioned single drugs. Each medication regimen is also marked with the number of organoids tested (n cases). The results showed that, in general, the combination of doxorubicin and atezolizumab was more effective than both single drugs, and the two had a significant synergistic effect; and, this combination regimen was superior to other tested regimens, confirming its huge application potential.
[0072] from Fig.10 It can be seen that this is the TGI result after more different drug regimens were treated in the PDO (75 cases) of these BS patients in a retrospective cohort of 75 patients. In order to meet the clinical testing needs of patients at the same time (i.e., guiding the clinical treatment of patients based on the results of organoid drug sensitivity testing), in addition to the use of anthracycline chemotherapy drugs, immune checkpoint inhibitors, and the combination of anthracycline chemotherapy drugs and immune checkpoint inhibitors for testing, the drug regimen selection and testing are mainly based on authoritative clinical practice guidelines (covering standard medication regimens), clinical studies and trials included in PubMed, MDT recommendations, and other evidence-based medicine. Next, the drug regimens used in ≥3 PDOs were screened, and the TGI of these regimens in each PDO tested was counted. The results showed that, overall, in a larger range of PDO samples, the TGI of the combination of doxorubicin and atezolizumab was significantly the highest, indicating that this combination regimen is the best in effectively killing tumor cells and is superior to other tested regimens.
[0073] from Fig.11 It can be seen that in PDO of patients with osteosarcoma, soft tissue sarcoma (various different types), Ewing sarcoma, head and neck squamous cell carcinoma, colorectal cancer, endometrial cancer, breast cancer, and gastric cancer, the combination of doxorubicin and atezolizumab showed a broad-spectrum anti-tumor effect, indicating that this combination therapy is suitable for a variety of malignant solid tumors.
[0074] from Fig.12 , Fig.13 , Fig.14It is known that a 47-year-old male patient (patient 01) with undifferentiated pleomorphic sarcoma (a type of soft tissue sarcoma) of the distal left femur was initially diagnosed with high-grade sarcoma by puncture biopsy. After receiving standard neoadjuvant treatment with a combination of doxorubicin, cisplatin and ifosfamide, he underwent left distal femoral bone tumor resection + knee replacement. After surgical resection of the tumor, pathological diagnosis was confirmed as undifferentiated pleomorphic sarcoma. Pathological sections showed that the tumor necrosis rate (TNR) was only 20%, indicating that standard neoadjuvant treatment was not effective. By constructing the PDO of his surgically resected tumor sample and performing drug sensitivity testing, the results showed that the combination therapy based on doxorubicin and atezolizumab had the highest TGI and may be the most promising treatment option. After comprehensive consideration by the attending physician and full knowledge of the patient, the patient clinically accepted the combination therapy for adjuvant treatment. The patient was followed up for 9 months, and until the last follow-up, the patient was still disease-free: the tumor did not recur after the resection of the distal femoral bone tumor; and the patient did not experience serious treatment-related adverse reactions. Therefore, the clinical follow-up results of this patient demonstrated the effectiveness and safety of this combination drug regimen.
[0075] from Fig.15 , Fig.16 , Fig.17 It can be seen that a 20-year-old male patient (patient 02) with osteosarcoma in the right foot was initially diagnosed with high-grade sarcoma by puncture biopsy. After receiving standard neoadjuvant treatment with a combination of doxorubicin and ifosfamide, he underwent amputation of the right foot malignant tumor. After surgical resection of the tumor, pathological diagnosis was malignant peripheral nerve sheath tumor (a type of soft tissue sarcoma). Pathological sections showed that the TNR was only 50%, indicating that the standard neoadjuvant treatment was not effective. Before the operation, a micrometastasis was found in his left lower lobe. By constructing the PDO of his surgically resected tumor sample and performing drug sensitivity testing, the results showed that the combination of doxorubicin and atezolizumab had the highest TG I and may be the most promising treatment option. After comprehensive consideration by the attending physician and full knowledge of the patient, the patient received adjuvant treatment based on the combination of doxorubicin and adebelimumab (both anti-PD-L1 antibody immunotherapy drugs). The patient was followed up for 10 months, and until the last follow-up, the patient was still in a state of no disease progression: the tumor did not recur after right foot amputation, the micrometastasis in the left lung did not increase, and the patient did not experience serious treatment-related adverse reactions. Therefore, the clinical follow-up results of this patient demonstrated the effectiveness and safety of this combination drug regimen.
[0076] The combined drug regimen provided by the present invention can effectively kill tumor cells in PDO of patients with osteosarcoma, soft tissue sarcoma, Ewing's sarcoma, head and neck squamous cell carcinoma, colorectal cancer, endometrial cancer, breast cancer, and gastric cancer, and has a broad spectrum of anti-tumor effects; in BS, the combined drug regimen is superior to single-agent anthracycline chemotherapy drugs and single-agent immune checkpoint inhibitors, has a significant synergistic effect, and is superior to the traditional standard drug regimen of BS; further, the combined drug regimen has demonstrated effectiveness and safety in the clinical treatment of patients with bone and soft tissue tumors, and can be used as a potential new treatment for malignant tumors represented by BS. In particular, the combined drug regimen currently belongs to OLDU, so it has broad clinical application prospects and great potential to enter clinical guidelines.
[0077] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. Use of an anthracycline and an immune checkpoint inhibitor in the preparation of a medicament for treating a tumor or enhancing an anti-tumor effect in a subject, wherein the anthracycline and the immune checkpoint inhibitor are administered to the subject simultaneously or sequentially.
2. A drug combination product of an anthracycline and an immune checkpoint inhibitor for use in treating a tumor or enhancing an anti-tumor effect in a subject, wherein the anthracycline and the immune checkpoint inhibitor are administered to the subject simultaneously or sequentially.
3. A method for treating tumors, comprising administering an effective amount of anthracycline and an immune checkpoint inhibitor simultaneously or sequentially to a subject in need thereof.
4. The use, pharmaceutical combination or method according to any one of claims 1 to 3, wherein the anthracycline is doxorubicin, liposome doxorubicin, epirubicin, daunorubicin, pirarubicin, legurubicin or carrubicin.
5. The use, pharmaceutical combination product or method according to any one of claims 1 to 3, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.
6. The use, pharmaceutical combination product or method according to any one of claims 1 to 3, wherein the tumor is osteosarcoma, soft tissue sarcoma, Ewing's sarcoma, head and neck squamous cell carcinoma, colorectal cancer, endometrial cancer, breast cancer, or gastric cancer.
7. A pharmaceutically acceptable composition comprising: Anthracyclines and immune checkpoint inhibitors.
8. A kit comprising: Anthracyclines and immune checkpoint inhibitors.
9. The pharmaceutically acceptable composition or kit according to claim 7 or 8, wherein the anthracycline is doxorubicin, liposome doxorubicin, epirubicin, daunorubicin, pirarubicin, legurubicin, or carrubicin.
10. The pharmaceutically acceptable composition or kit according to claim 7 or 8, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody, and the anti-PD-L1 antibody is: atezolizumab, envolimab, adebelimumab, durvalumab, sugemalimab, socazolimab, etc.
